Autologous stem cell transplantation normalizes abnormal bone remodeling and sRANKL/osteoprotegerin ratio in patients with multiple myeloma

This publication has 32 references indexed in Scilit:

• Serum levels of macrophage inflammatory protein‐1 alpha (MIP‐1α) correlate with the extent of bone disease and survival in patients with multiple myeloma
  British Journal of Haematology, 2003
• Soluble receptor activator of nuclear factor κB ligand–osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index
  Blood, 2003
• High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
  New England Journal of Medicine, 2003
• RANK ligand and osteoprotegerin in myeloma bone disease
  Blood, 2003
• Multiple myeloma: evolving genetic events and host interactions
  Nature Reviews Cancer, 2002
• Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression
  Proceedings of the National Academy of Sciences, 2001
• Diverse roles of the tumor necrosis factor family member TRANCE in skeletal physiology revealed by TRANCE deficiency and partial rescue by a lymphocyte-expressed TRANCE transgene
  Proceedings of the National Academy of Sciences, 2000
• Biochemical markers of bone metabolism reflect osteoclastic and osteoblastic activity in multiple myeloma
  European Journal of Haematology, 2000
• CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
  British Journal of Haematology, 1998
• A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma
  New England Journal of Medicine, 1996